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Introduction
Pulmonary arterial hypertension (PAH) is a severe, progres-
sive disease, which can present idiopathically or secondary to
conditions such as systemic sclerosis or congenital heart
disease (CHD) [1]. In the setting of CHD-PAH a systemic-to-
pulmonary shunt and increased volume overload ultimately
lead to adaptations of pulmonary vasculature and endothelial
dysfunction. The classification of CHD-PAH has recently
been updated to include four categories: (1) Eisenmenger
syndrome, (2) PAH associated with systemic-to-pulmonary
shunts, (3) PAH with small septal defects and (4) PAH after
corrective cardiac surgery or intervention. Three classes of
advanced therapy for PAH are currently in use: prostanoids
such as epoprostenol, endothelin-1 receptor antagonists such
as bosentan and phosphodiesterase 5 inhibitors such as
sildenafil.
Eisenmenger syndrome
Nowadays, all patients with class III Eisenmenger
syndrome should be treated according to the current
guidelines, based on a class IC recommendation [2]. In
our nationwide study with a standardised treatment protocol
we observed a prolonged beneficial effect of bosentan
treatment on exercise capacity, echocardiographic stroke
volume and quality of life in CHD-PAH patients (79%
Eisenmenger syndrome) [3]. In Eisenmenger patients with
Down syndrome a stabilisation of clinical parameters was
seen.
Expanding indications
Indications for advanced therapy are expanding. In NYHA
functional class II PAHpatients, short-term efficacy of bosentan
has been demonstrated. Moreover, prevention of clinical
deterioration should be considered an important treatment goal.
Some patients with complex CHD have peripheral
pulmonary artery stenosis resulting in local variation of
pulmonary artery arterial pressure. Consequently, some
segments of pulmonary tissue have higher pressures than
others; therefore, the term segmental PAH has been
suggested to describe this situation [4]. Our group has
reported a case series with segmental PAH demonstrating
improvement of NYHA functional class and exercise
capacity after 12 months of bosentan treatment.
Surgical patients
Patients with septal defects and severe or irreversible PAH
are by convention ineligible for cardiac surgery. However, a
number of these patients can benefit from advanced therapy
as a bridge to surgical intervention. In the literature a few
cases have been reported on CHD-PAH patients who
became eligible for cardiac surgery after bosentan treatment
[5].
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CHD patients who undergo cardiac surgery tend to have
a decline in right ventricular function, and advanced
therapy might be useful to prevent this decline. Cardiopul-
monary bypass initiates an endothelin-1 release, which
induces vasoconstriction of the pulmonary arterioles result-
ing in elevation of the pulmonary vascular resistance
(PVR). In a small study, perioperative treatment with a
selective endothelin-1 receptor antagonist led to a signifi-
cant decrease in PVR compared with the control group [6].
A study on sildenafil treatment one week upon institution
of cardiopulmonary bypass in 23 children with PAH found
shortening of cardiopulmonary bypass time, mechanical
ventilation time, and length of intensive care unit and
hospital stays [7]. Large prospective randomised trials are
needed to confirm this hypothesis and to show clinical
benefit in CHD patients.
Fontan patients
Another patient category that might benefit from ad-
vanced therapy is patients with a Fontan circulation. Low
PVR is crucial for Fontan patients. Advanced therapy,
which acts on PVR, might lead to an increase in
transpulmonary flow and ventricular preload and thereby
improve cardiac output and exercise performance in
Fontan patients. In a first randomised double-blind
placebo-controlled trial, Goldberg et al. found an im-
provement in ventilatory efficiency and submaximal
exercise capacity after six weeks of sildenafil treatment
[8]. However, no significant improvement in six-minute
walking distance was seen in a small group (n=10) of
failing Fontan patients treated with bosentan for 12 weeks.
In the Netherlands, we are currently performing a prospec-
tive randomised trial on bosentan in Fontan patients; the
results are expected in spring 2012.
Future perspectives
Recent research in non-CHD patients has provided new
insights into the pathophysiology, diagnosis and manage-
ment of PAH [5, 9–11].
The pathophysiological changes of the pulmonary
arteries in pulmonary hypertension include endothelial
damage and proliferation and hypercontractility of vascu-
lar smooth muscle cells. However, inflammation may
also be involved in the pathogenesis of PAH. Some
patients with idiopathic PAH have immunological dis-
turbances (e.g., circulating autoantibodies, such as anti-
nuclear antibodies) and elevated circulating levels of pro-
inflammatory cytokines (e.g., interleukin-1 and -6) [12]. It
has been demonstrated that Rho-kinase is upregulated by
inflammatory stimuli, and the Rho-kinase pathway may
play an important role in the development of PAH. Efficacy
of fasudil, a Rho-kinase inhibitor, is currently under
investigation.
Platelet-derived growth factor (PDGF) and its receptor
(PDGFR) have also been implicated in the pathobiology
of PAH. PDGF induces proliferation and migration of
human pulmonary artery smooth muscle cells. Imatinib, a
tyrosine kinase inhibitor of PDGFR, has been shown safe
in PAH patients and a Phase III efficacy trial is in
progress [13].
Results of these ongoing studies on fasudil and imatinib
should be awaited, and similar studies should be started in
CHD-PAH patients.
Conclusion
Following current guidelines, all patients with Eisenmenger
syndrome in class III should be treated with advanced
therapy. Surgical CHD patients could benefit from ad-
vanced treatment perioperatively. PAH patients initially
ineligible for cardiac surgery could benefit from advanced
therapy as a bridge to intervention. The first results of
studies on advanced therapy in CHD-PAH class II patients,
segmental PAH patients and Fontan patients point towards
benefit.
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